APG has identified a new way of reducing aggregation of mutated huntingtin. The drug candidate is a small molecule, which may be applied orally.
Recently, we could demonstrate that our lead compound improves significantly motor symptoms in a rodent model of Huntington Disease.
We are at Bio Europe 2019 in Hamburg, Germany.
APG has received an EU grant by the PERMIDES initiative to establish an in silico drug discovery platform.
We have currently one drug discovery program: Huntington's disease. We want to expand to other neurodegenerative indications.
We presented at BioEurope on November 6-8 2017 at the CityCube in Berlin.